Search

Celldex Therapeutics Inc

Закрыт

СекторЗдравоохранение

41.92 -1.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

40.79

Макс.

42.36

Ключевые показатели

By Trading Economics

Доход

5.2M

-74M

Продажи

7K

22K

Прибыль на акцию

-0.94

Рентабельность продаж

-334,104.545

Сотрудники

198

EBITDA

5.2M

-73M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+37.97% upside

Дивиденды

By Acuity

Следующий отчет о доходах

6 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

416M

3.4B

Предыдущая цена открытия

42.96

Предыдущая цена закрытия

41.92

Celldex Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 20:06 UTC

Celldex Therapeutics Inc shares are lower today amid mixed market sentiment following a decline in U.S. retail sales for July.

13 авг. 2026 г., 20:06 UTC

Celldex Therapeutics shares are lower today, continuing a decline since Wednesday amid rising initial jobless claims in the U.S.

12 авг. 2026 г., 19:56 UTC

Celldex Therapeutics Inc is higher today, maintaining a positive trend after closing up in the last seven sessions. The stock pulled back slightly from an earlier peak.

11 авг. 2026 г., 20:06 UTC

Celldex Therapeutics Inc shares are higher today, marking six consecutive sessions of gains. The stock remains significantly above its 20-day moving average.

10 авг. 2026 г., 19:16 UTC

News

Celldex Therapeutics shares are higher as Barclays and Morgan Stanley raise price targets to $53.00 and $46.00, respectively, maintaining overweight ratings.

7 авг. 2026 г., 19:11 UTC

News

Celldex Therapeutics shares are lower despite Morgan Stanley and Barclays raising price targets to $46 and $53, respectively. Broader market volatility persists.

5 авг. 2026 г., 20:01 UTC

Celldex Therapeutics Inc shares are trading higher amid a positive market backdrop, supported by declining oil prices and optimism over U.S.-Iran negotiations.

4 авг. 2026 г., 19:56 UTC

Celldex Therapeutics Inc shares are higher today, supported by overall market strength amid a decline in crude oil prices. No specific company news was identified.

3 авг. 2026 г., 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31 июл. 2026 г., 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30 июл. 2026 г., 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29 июл. 2026 г., 20:03 UTC

Macro Event
News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28 июл. 2026 г., 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27 июл. 2026 г., 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22 июл. 2026 г., 20:01 UTC

Event
News
Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 июл. 2026 г., 23:01 UTC

Social Media
Event
News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Сравнение c конкурентами

Изменение цены

Celldex Therapeutics Inc Прогноз

Целевая цена

By TipRanks

37.97% рост

Прогноз на 12 месяцев

Средняя 58.79 USD  37.97%

Максимум 100 USD

Минимум 38 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Celldex Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

13

Покупка

1

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat